Newsroom

Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, has agreed to issue bonds with an aggregate principal amount of USD 1.5 billion across two tranches.

Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, has filed the annual report 2020 on form 20-F with the U.S. Securities and Exchange Commission (SEC).

Throughout 2020, Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, reported COVID-19 affecting patients with advanced kidney disease and, in particular, the severity of illness resulting in an increased mortality.

Fresenius Medical Care has improved in this year's ranking of the non-profit organization CDP (formerly "Carbon Disclosure Project").